Spots Global Cancer Trial Database for treatment naïve
Every month we try and update this database with for treatment naïve cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy | NCT03069352 | Acute Myeloid L... | Placebo Venetoclax Cytarabine | 18 Years - | AbbVie | |
A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) | NCT05785767 | Advanced Non-Sm... | fianlimab cemiplimab Placebo | 18 Years - | Regeneron Pharmaceuticals | |
A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) | NCT05785767 | Advanced Non-Sm... | fianlimab cemiplimab Placebo | 18 Years - | Regeneron Pharmaceuticals | |
A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma | NCT04212013 | Marginal Zone L... | Ibrutinib Rituximab Placebo | 18 Years - | Memorial Sloan Kettering Cancer Center | |
A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma | NCT04212013 | Marginal Zone L... | Ibrutinib Rituximab Placebo | 18 Years - | Memorial Sloan Kettering Cancer Center | |
Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular Lymphoma | NCT03828448 | Follicular Lymp... Small Lymphocyt... | Ublituximab Umbralisib | 18 Years - | TG Therapeutics, Inc. |